Coya Therapeutics, Inc. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Coya completed enrollment of 137 participants (vs. 120 planned) in its Phase 2/3 ALSTARS trial of COYA 302 for ALS treatment. The company holds $35.8M cash as of Sept 30, 2026, sufficient to fund operations past the Q2 2027 topline readout into H2 2027. Q3 2026 net loss was $10.6M (vs. $2.1M in Q3 2025); R&D expenses rose $5.7M driven by clinical trial advancement.
Why this rating
Trial completion is material clinical milestone for $89M biotech; $35.8M cash runway covers key catalyst. Elevated Q3 burn rate concerning but expected during trial execution phase.
Tradability signal
NO TRADE
No trade: positive news with only -1.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.11% over 4 hrs, n=417). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $3.18 | +10 min · unknown $3.25 ▲ 2.36% | +30 min · unknown $3.41 ▲ 7.23% | +1 hr · unknown $3.41 ▲ 7.23% | +4 hrs · unknown $3.21 ▲ 0.94% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.